.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Deloitte
Moodys
Fuji
Citi
Fish and Richardson
Julphar
UBS
Cantor Fitzgerald
Baxter

Generated: November 21, 2017

DrugPatentWatch Database Preview

Emd Serono Inc Company Profile

« Back to Dashboard

What is the competitive landscape for EMD SERONO INC, and what generic alternatives to EMD SERONO INC drugs are available?

EMD SERONO INC has two approved drugs.

There is one US patent protecting EMD SERONO INC drugs.

There are twenty-five patent family members on EMD SERONO INC drugs in twenty-two countries and three supplementary protection certificates in three countries.

Summary for Emd Serono Inc

International Patents:25
US Patents:1
Tradenames:2
Ingredients:2
NDAs:2
Drug Master File Entries: 1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Emd Serono Inc
GEREF
sermorelin acetate
INJECTABLE;INJECTION020443-001Sep 26, 1997DISCNYesNo► Subscribe► Subscribe► Subscribe
Emd Serono Inc
CETROTIDE
cetrorelix
INJECTABLE;INJECTION021197-001Aug 11, 2000RXYesYes► Subscribe► Subscribe ► Subscribe
Emd Serono Inc
CETROTIDE
cetrorelix
INJECTABLE;INJECTION021197-002Aug 11, 2000DISCNNoNo► Subscribe► Subscribe ► Subscribe
Emd Serono Inc
GEREF
sermorelin acetate
INJECTABLE;INJECTION020443-002Sep 26, 1997DISCNYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Emd Serono Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Emd Serono Inc
CETROTIDE
cetrorelix
INJECTABLE;INJECTION021197-002Aug 11, 2000► Subscribe► Subscribe
Emd Serono Inc
GEREF
sermorelin acetate
INJECTABLE;INJECTION020443-001Sep 26, 1997► Subscribe► Subscribe
Emd Serono Inc
GEREF
sermorelin acetate
INJECTABLE;INJECTION020443-002Sep 26, 1997► Subscribe► Subscribe
Emd Serono Inc
CETROTIDE
cetrorelix
INJECTABLE;INJECTION021197-001Aug 11, 2000► Subscribe► Subscribe
Emd Serono Inc
CETROTIDE
cetrorelix
INJECTABLE;INJECTION021197-001Aug 11, 2000► Subscribe► Subscribe
Emd Serono Inc
CETROTIDE
cetrorelix
INJECTABLE;INJECTION021197-001Aug 11, 2000► Subscribe► Subscribe
Emd Serono Inc
CETROTIDE
cetrorelix
INJECTABLE;INJECTION021197-002Aug 11, 2000► Subscribe► Subscribe
Emd Serono Inc
CETROTIDE
cetrorelix
INJECTABLE;INJECTION021197-002Aug 11, 2000► Subscribe► Subscribe
Emd Serono Inc
CETROTIDE
cetrorelix
INJECTABLE;INJECTION021197-002Aug 11, 2000► Subscribe► Subscribe
Emd Serono Inc
CETROTIDE
cetrorelix
INJECTABLE;INJECTION021197-001Aug 11, 2000► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Emd Serono Inc Drugs

Country Document Number Estimated Expiration
European Patent Office1082129► Subscribe
Australia752415► Subscribe
World Intellectual Property Organization (WIPO)9955357► Subscribe
Portugal1082129► Subscribe
Russian Federation2221588► Subscribe
Australia3702899► Subscribe
Israel139027► Subscribe
Hungary228736► Subscribe
Slovakia15302000► Subscribe
Brazil9909802► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Emd Serono Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90029Netherlands► SubscribePRODUCT NAME: CETRORELIX, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAAR DBAAR ZUUR ADDITIEZOUT, IN HET BIJZONDER CETRORELIX ACETAAT; REGISTRATION NO/DATE: EU/1/99/100/001-003 19990413
/1999Austria► SubscribePRODUCT NAME: CETRORELIX UND PHARMAZEUTISCH ANNEHMBARE SAEUREADDITIONSSALZE DAVON, INSBESONDERE CETRORELIXACETAT; REGISTRATION NO/DATE: EU/1/99/100/001- EU/1/99/100/003 19990413
9C0031Belgium► SubscribePRODUCT NAME: ACETATE DE CETRORELIX; REGISTRATION NO/DATE: EU/1/99/100/001 19990413
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Argus Health
Fuji
Novartis
Chubb
Accenture
Express Scripts
McKinsey
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot